MAxL -
Munich Accelerator Life Sciences & Medicine

With MAxL we create the perfect framework conditions for successful start-ups. 

MAxL is BioM's unique co-creation start-up incubator for the future of medicine and life sciences located in Martinsried/Munich, the European hotspot for biotech.

Based on BioM’s strong expertise, MAxL supports selected pre-seed and early-stage start-up teams with an exclusive high-end infrastructure: shared lab space, co-working and community space for pre-seed and early start-up teams from Bavaria and beyond, structured incubation and coaching program, fully equipped lab workspaces, co-working spaces, meeting and event spaces, and numerous networking opportunities.

We offer partnerships with pharma, big biotech, deeptech and other industry players and strategic partners, CROs and investors.

The project is funded with EUR 8.5 million from 2023-2027 by the Bavarian State Ministry of Economic Affairs, Regional Development and Energy and is managed by the cluster management company BioM.

With MAxL, pre-seed projects and start-ups from life sciences and healthtech receive precisely targeted support:


•       on around 900 m2 in close proximity to BioM - from from mid-May 2024 onwards


  • Innovative therapeutics (all modalities, including ATMPs such as gene therapy, cell therapy, vaccines)
  • Platform technologies for drug discovery, drug development, drug and vaccine production
  • Next-generation diagnostics and diagnostic platforms
  • Health tech business models based on digital health, Big Data, machine learning and AI
  • Biotechnology-based solutions in the area of bioeconomy


Interested? We are happy to get in touch with you!

Dr. Petra Burgstaller
Dr. Petra Burgstaller

Incubation & MAxL Co-Lead, Portfolio Management

Christina Enke-Stolle
Christina Enke-Stolle

Incubation & MAxL Co-Lead, Partnership Management

More about this topic

BIO-Europe 2024 in Stockholm, Sweden: Join us at the German Pavilion!

BIO-Europe 2024: Out­stand­ing Offer at the Ger­man Pavil­ion – Se­cure Your Spot Now!This fall, BIO-Europe re­turns for an en­rich­ing…

Eisbach Bio announces FDA clearance of IND application for EIS-12656, a first-in-class allosteric inhibitor of ALC1

Eis­bach Bio GmbH, a privately-held clin­ic­al-stage bi­o­tech­no­logy com­pany in Martin­sried pi­on­eer­ing can­cer medi­cines lever­aging…